• LAST PRICE
    4.3300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.0600/ 4
  • Ask / Lots
    5.4900/ 47
  • Open / Previous Close
    4.3000 / 4.3300
  • Day Range
    Low 4.2016
    High 4.4000
  • 52 Week Range
    Low 1.8306
    High 8.8600
  • Volume
    25,672
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 4.33
TimeVolumeDBTX
09:32 ET1624.3
09:38 ET1274.2016
09:41 ET1004.4
10:03 ET4004.37
10:08 ET2004.25
10:14 ET2004.25
10:35 ET2664.25
10:55 ET1004.275
11:22 ET2664.25
11:36 ET4004.28
11:42 ET6304.25
11:45 ET51034.26
12:16 ET2004.39
12:41 ET9004.39
12:43 ET2004.36
12:45 ET1004.38
12:50 ET9004.3873
12:52 ET15724.32
01:03 ET1004.3202
01:06 ET3004.32
01:30 ET2004.35
01:32 ET2004.35
02:06 ET1004.31
02:18 ET8754.33
02:20 ET2404.31
02:22 ET5004.3
02:29 ET3004.32
03:03 ET1004.355
03:25 ET1884.36
03:38 ET13004.32
03:41 ET18174.27
03:45 ET2004.27
03:48 ET2004.31
03:50 ET1004.3
03:52 ET5004.305
03:57 ET1004.335
03:59 ET12214.33
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDBTX
Decibel Therapeutics Inc
107.1M
-2.0x
---
United StatesLIFE
aTyr Pharma Inc
104.6M
-2.0x
---
United StatesDARE
Dare Bioscience Inc
104.2M
-2.7x
---
United StatesRZLT
Rezolute Inc
101.4M
-1.0x
---
United StatesANEB
Anebulo Pharmaceuticals Inc
97.8M
-2.7x
---
United StatesNCNA
NuCana PLC
80.9M
-1.8x
---
As of 2022-08-14

Company Information

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.

Contact Information

Headquarters
1325 Boylston Street, Suite 500BOSTON, MA, United States 02215
Phone
617-370-8701
Fax
302-655-5049

Executives

Independent Chairman of the Board
William Carson
President, Chief Executive Officer, Director
Laurence Reid
Founder
Gabriel Corfas
Founder
M. Charles Liberman
Founder
Ulrich Mueller

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$107.1M
Revenue (TTM)
$0.00
Shares Outstanding
25.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.21
Book Value
$5.68
P/E Ratio
-2.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.